Gilead dishes out $66M for San Diego biotech’s ‘tentacles’ in cancer, inflammation

Gilead will pony up $66 mil­lion in an up­front pay­ment and eq­ui­ty in­vest­ment to col­lab­o­rate with Ten­tar­ix Bio­ther­a­peu­tics on bi­o­log­ics for in­flam­ma­to­ry dis­eases and on­col­o­gy, the com­pa­nies said Tues­day morn­ing.

San Diego-based Ten­tar­ix could re­ceive up to an­oth­er $240 mil­lion if Gilead elects to ac­quire three of the biotech’s sub­sidiaries that house the on­col­o­gy and in­flam­ma­to­ry dis­ease pro­grams in­clud­ed in the pact, the part­ners said. That fig­ure would be split even­ly across the three pro­grams, which use the start­up’s so-called Ten­ta­cles plat­form.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.